Howard Robin (again) mentioned the possibility of 214 possibly being approved in Sarcoma on the one study given how poor outcomes are in that patient population. Not being a big oncology investor how plausible do you think that is?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.